"Little Fighters, Big Hope" apparel sale on Bonfire

You can now show your support and help spread awareness by purchasing items from our new collection, including shirts and sweatshirts in a variety of styles and colors!

➡️ Shop the "Little Fighters, Big Hope" collection here: bonfire.com/hope4atrt/

OR, make it personal! If you're looking for a unique way to make an impact, you can also start your own shirt fundraiser! Customize the design with your warrior's name to rally your community and raise even more vital funds.

➡️ Launch your customized fundraiser here: bonfire.com/event/hope4-atrt/

Thank you for being a part of our mission and helping us create a brighter future for children fighting ATRT. Your support makes a world of difference!

ATRT Research Update

Lantern Pharma Inc. (Nasdaq: LTRN)'s drug candidate, LP-184 shows promising in-vivo activity in Atypical Teratoid Rhabdoid Tumors at 2025 Society for Neuro-Oncology Pediatric Conference.

Independent research from Johns Hopkins Medicine, presented by Dr. Eric Raabe at the 2025 SNO Pediatric Neuro-Oncology Conference, supports Lantern’s data that led to their FDA Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 for the treatment of ATRT.

In-Vivo Data Highlights:

• In-vivo mice models, CHLA06 and BT37, showed survival of increases of 345% and 44% respectively.

• Potent anti-tumor activity across multiple ATRT subtypes (MYC, TYR, SHH)

• Strong blood-brain barrier penetration (Cmax: 730 nM)

• Increased apoptosis(programmed cell death), reduced proliferation in ATRT cancer cells

• Significant survival benefit in two orthotopic xenograft models

• No observed toxicity in vivo

These findings support the planned pediatric clinical trial of LP-184 expected to begin in late 2025 or early 2026.

View the full press release: https://bit.ly/4jrJqF8

Live Interview with Dr. Trisha Larkin

Dr. Trisha Larkin is dual-board certified in Pediatrics and Pediatric Hematology-Oncology with an expertise in Pediatric Neuro-Oncology. She serves as the Director of Pediatric Neuro-Oncology at St. Joseph’s Children’s Hospital in Tampa, FL.

Dr. Larkin’s career is dedicated towards expanding clinical growth, research, and clinical trial offerings for children battling central nervous system tumors. Dr. Larkin earned her medical degree from Florida International University in Miami, followed by a Master of Business Administration with a focus in healthcare. She completed her postdoctoral pediatric training at Nicklaus Children’s Hospital, followed by a fellowship in pediatric hematology-oncology and bone marrow transplantation at the University of Florida in Gainesville. She then completed an advanced fellowship in Pediatric Neuro-oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee where she worked on a team of world-renowned physicians and researchers to care for children diagnosed with complex brain and spinal tumors.

Dr. Larkin is passionate about discovering innovative strategies to improve the care of children with brain tumors. Her research interests include early-phase clinical trials and drug development. Dr. Larkin has presented her research in pediatric central nervous system tumors at national and international meetings across the states as well as in Karuizawa, Japan and Hamburg, Germany. Dr. Larkin has published numerous peer-reviewed articles in prestigious journals such as the Journal of Clinical Oncologyand Neuro-Oncology. She serves as associate editor for Neuro-Oncology on the MedNet, an interactive platform for physicians around the world to gather insight about treating complex oncologic diagnoses. She is a member of the American Society of Pediatric Hematology-Oncology, Society for Neuro-Oncology, Children’s Oncology Group, Society for Pediatric Research, American Society of Clinical Oncology, and American Academy of Pediatrics.